CSTL
Castle Biosciences, Inc. · Healthcare · Medical - Diagnostics & Research
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 76 | -1 | 16.83M | $401.45M | +6 | −6 |
| Q1 2026 | 79 | -9 | 16.13M | $395.93M | +4 | −13 |
| Q4 2025 | 87 | +2 | 17.12M | $665.58M | +2 | — |
| Q3 2025 | 16 | 0 | 9.41M | $214.29M | +1 | −1 |
| Q2 2025 | 13 | -1 | 9.39M | $191.81M | — | −1 |
| Q1 2025 | 11 | 0 | 4.13M | $82.76M | +1 | −1 |
| Q4 2024 | 11 | +2 | 4.84M | $128.97M | +4 | −2 |
| Q3 2024 | 8 | 0 | 2.64M | $75.25M | — | — |
| Q2 2024 | 8 | — | 1.95M | $42.47M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Citadel Advisors ✦ | 693.38K | — | $15.09M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 617.68K | — | $13.45M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Renaissance Technologies ✦ | 301.50K | — | $6.56M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Marshall Wace ✦ | 212.04K | — | $4.62M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Point72 Asset Management ✦ | 53.78K | — | $1.17M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Millennium Management ✦ | 34.83K | — | $758,184 | 0.0% | n/c | 1 | SEC ↗ |
| 7 | T. Rowe Price ✦ | 20.65K | — | $450,000 | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Two Sigma Investments ✦ | 16.80K | — | $365,736 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 186 holders, 27.52M shares, $653.08M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 3.20K sh · $113,740
Officer, Director · 8.58K sh · $305,156
Officer, Director · 2.72K sh · $96,668
Officer · 1.35K sh · $48,967
Officer · 2.81K sh · $100,350
Officer · 1.03K sh · $35,363
Officer · 5.54K sh · $196,765
Officer, Director · 8.58K sh · $303,166
Officer, Director · 2.72K sh · $96,038
Officer, Director · 3.20K sh · $112,998
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology